July 6,"Top 100 Enterprises in Main Business of China Pharmaceutical Industry in 2024"In the42nd National Annual Conference on Pharmaceutical Industry Information and 2025 Beijing·Changping Life Science ForumPublished on.

01
"Top 100 Chinese Pharmaceutical Enterprises in Main Business Revenue for 2024" Released

In 2024,China National Pharmaceutical Group Corporation Ranks First for Five Consecutive Years, CR PHARMA COMM and Qilu Pharmaceutical Secure Second and Third Places Respectively; The positions of Yuanda Group and Fosun Pharma were swapped, ranking fourth and fifth respectively; while CSPC continued to rank sixth. The pattern of the leading group remained stable, with the strong remaining strong.

However, significant changes occurred in the 7th to 10th positions in 2024, with three new companies making their debut: Novo Nordisk (China) entered the top ten for the first time due to the market performance of its GLP-1 receptor agonist semaglutide and next-generation insulin products; Hengrui Medicine returned, demonstrating the success of its R&D transformation with 49.6% of its revenue coming from innovative drugs; and Zhengdatianqing benefited from its recently approved biosimilars and new drugs, as well as the introduction of high-value products.

In 2024, eight new companies joined the top 100, respectively.Beijing Tong Ren Tang, Sichuan Baili Pharmaceutical, Asymchem Laboratories, Haleon (Suzhou) Pharmaceutical, GlaxoSmithKline Tianjin, Holi Pharmaceutical Group, Huapont Life Health, and Yifan Pharmaceutical.

The successful advancement of these enterprises is attributed to their respective differentiated competitive advantages. For instance, Baili Pharmaceutical achieved a more than 10-fold leap in its main business revenue compared to the previous year, driven by strong authorized income, propelling the company into the 53rd position among the top 100. On the other hand, Yifan Pharmaceutical successfully entered the top 100 mainly due to the commercial scaling up of new products.

DataDerived from the only official source reflecting the economic operation of China's pharmaceutical industry, the "China Pharmaceutical Industry Statistical Yearbook"，Extracted from the comprehensive annual report, ranked by main business revenue.Top 100 enterprises.

02

Differentiation in the pharmaceuticals industry intensifies

Leading enterprises face pressure from in-depth adjustments

CPhI China learned on the conference site that the "Top 100 Enterprises in China's Pharmaceutical Industry by Main Business Revenue in 2024" achieved a total main business revenue of 1,004.97 billion yuan, a decrease of 2.5% compared to 2023 (1,030.19 billion yuan), while the total profit reached 209.31 billion yuan, an increase of 0.9% from the previous year.

PharmSnap Media Business Cooperation

Media Public Relations | News &Press Release

Manager Zhang: 18600036371 (Same for WeChat)

Click "Yao Du" below to follow more exciting content.

The push rules of WeChat Official Accounts have changed again. If you don't tap"Under observation"Or not set to"Star Mark", we might just dissipate in the vast sea of text~ Click here, don't miss out on the latest news from PharmaGuide!??